Novel therapy for myelodysplastic syndrome
Part of Blood & lymphatic clinical trials.
This study tests a new combination treatment for people with myelodysplastic syndrome (MDS), a blood disorder. The drug aims to slow the disease and improve blood counts, and might be an option for patients who haven't responded to other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 20 years or older
- You must have a diagnosis of MDS (including certain subtypes like refractory anemia or chronic myelomonocytic leukemia)
- Your cancer must be at a certain risk level (low or intermediate-1) and you've either not responded to other treatments or are currently taking azacitidine injections, OR your cancer is at a higher risk level (intermediate-2 or high)
- You must be generally active, able to care for yourself (ECOG score 0 or 1)
- Your liver, kidney, and lung function must be within acceptable limits
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational oral liquid called BLEX 404 taken together with a standard drug, azacitidine, for people with higher-risk MDS or CMML. It aims to see if the combination is safe and effective.
This study tests whether adding a new drug called iadademstat to the standard treatment ASTX727 helps people with advanced myeloproliferative neoplasms (blood cancers that cause the bone marrow to make too many cells). The goal is to see if the combination is safe and works better than the standard treatment alone.
This study compares two combinations of chemotherapy drugs to see which one works better for people with certain types of acute myeloid leukemia (AML) or a high-risk bone marrow disorder called MDS. The goal is to find a treatment that may help control the disease and improve quality of life.
This early-phase trial studies a new treatment plan (decitabine-related medicine with other targeted drugs, depending on the arm) for adults with MDS/MPN overlap syndromes. It aims to improve control of the disease by targeting the abnormal bone marrow cells. Because it’s Phase 1/2, the main goal is to find safe dosing and see whether it helps responses.
This study tests a combination of two drugs, azacitidine and rotercept, for people with a type of blood cancer called myelodysplastic syndrome (MDS) that has a higher risk of progressing. The goal is to see if adding rotercept helps control the disease better than standard care.
This trial tests a new oral medication (iadademstat) combined with a standard therapy called a hypomethylating agent for people with higher-risk myelodysplastic syndromes (MDS) or related blood cancers. The goal is to see if the combination is safe and effective.
Hear when a new Myelodysplastic Syndrome (MDS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.